Understanding the Market | JINHAI MED TECH rose over 5% during the trading session after recently reaching a cooperation agreement with David Medical. The company has already laid out the "Minimally Invasive 5.0" technology
I'm LongbridgeAI, I can summarize articles.JINHAI MED TECH's stock rose over 5% during the trading session, and as of the time of writing, it is up 4.4%, priced at HKD 1.66, with a trading volume of HKD 3.3692 million. In terms of news, recently, JINHAI MED TECH announced that its wholly-owned subsidiary, Shanghai JINHAI MED TECH Co., Ltd., has signed a five-year cooperation framework agreement with the wholly-owned subsidiary of Ningbo David Medical Devices Co., Ltd., Ningbo Weierkaidi Medical Devices Co., Ltd. According to the agreement, Shanghai JINHAI and the David Medical Group will work together to develop endoscopic products in the international market, aiming to create competitive high-end medical device solutions in the international market. It is reported that JINHAI MED TECH has become a representative enterprise of domestic high-end endoscopes due to breakthroughs in core technologies such as 4K ultra-high definition, 3D stereoscopic imaging, and fluorescence navigation. The company has laid out "Minimally Invasive 5.0" technology, including molecular probes, multispectral imaging, and AI-assisted diagnosis, with the goal of becoming a leader in the global medical imaging device field. Its newly developed products, such as the 8K endoscope system and mixed reality holographic imaging navigation system, will further consolidate its technological leadership
According to Zhitong Finance APP, JINHAI MED TECH (02225) rose over 5% during the trading session, and as of the time of writing, it is up 4.4%, priced at HKD 1.66, with a transaction volume of HKD 3.3692 million.
In terms of news, recently, JINHAI MED TECH announced that its wholly-owned subsidiary, Shanghai JINHAI MED TECH Co., Ltd., has signed a five-year cooperation framework agreement with the wholly-owned subsidiary of Ningbo David Medical Devices Co., Ltd. (300314.SZ), Ningbo Weierkaidi Medical Devices Co., Ltd. According to the agreement, Shanghai JINHAI and the David Medical Group will work together to develop endoscopic products in the international market, aiming to create competitive high-end medical device solutions in the international market.
It is reported that JINHAI MED TECH has become a representative enterprise of domestic high-end endoscopes due to breakthroughs in core technologies such as 4K ultra-high definition, 3D stereoscopic imaging, and fluorescence navigation. The company has laid out "Minimally Invasive 5.0" technology, including molecular probes, multispectral imaging, and AI-assisted diagnosis, with the goal of becoming a leader in the global medical imaging device field. Its newly developed products, such as the 8K endoscope system and mixed reality holographic imaging navigation system, will further consolidate its technological leadership